止血剂市场规模、份额、成长分析、按类型、按治疗方法、按最终用户、按地区 - 行业预测，2025 年至 2032 年

2023 年全球止血剂市场规模价值 73.8 亿美元，预计将从 2024 年的 80.3 亿美元成长到 2032 年的 157.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.8%。

由于出血性疾病和慢性病的发生率不断上升，尤其是在老龄化人口中，止血剂市场预计将经历显着增长。全球范围内外科手术的激增进一步增加了对先进止血药物的需求。根据世界卫生组织统计，每年有超过125万起道路交通事故导致严重出血，凸显了对此类药物的迫切需求。此外，机器人辅助手术等手术技术的进步也有望进一步推动市场需求。然而，手术费用高、报销政策不利以及发展中地区对最新技术创新缺乏认识等挑战可能会阻碍成长。解决这些障碍对于充分发挥市场的潜力至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

止血剂市场规模（按类型）

• 市场概况
• 凝血酶类止血剂
• 明胶基止血剂
• 胶原蛋白止血剂
• 氧化再生纤维素止血剂
• 纤维蛋白胶
• 其他的

止血剂市场规模（按治疗）

• 市场概况
• 心血管
• 一般外科
• 胃肠外科
• 神经外科
• 其他的

止血剂市场规模（按最终用户划分）

• 市场概况
• 医院
• 手术中心
• 疗养院
• 其他的

止血剂市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Baxter International Inc.（USA）
• Becton, Dickinson and Company（USA）
• Medtronic plc（Ireland）
• Stryker Corporation（USA）
• Sanofi SA（France）
• CSL Limited（Australia）
• Zimmer Biomet Holdings, Inc.（USA）
• Teleflex Incorporated（USA）
• CryoLife, Inc.（USA）
• Integra LifeSciences Holdings Corporation（USA）
• Mallinckrodt Pharmaceuticals（UK）
• B. Braun Melsungen AG（Germany）
• Terumo Corporation（Japan）
• Smith & Nephew plc（UK）
• Haemonetics Corporation（USA）
• Ethicon, Inc.（USA）
• The Medicines Company（USA）
• Anika Therapeutics, Inc.（USA）

结论和建议

Global Hemostatic Agents Market size was valued at USD 7.38 billion in 2023 and is poised to grow from USD 8.03 billion in 2024 to USD 15.77 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).

The Hemostatic Agents Market is poised for significant growth due to the increasing prevalence of bleeding disorders and chronic diseases, particularly among the aging population. The surge in surgical procedures worldwide further amplifies demand for advanced hemostasis medications. According to the World Health Organization, over 1.25 million road injury incidents annually contribute to severe bleeding, highlighting a pressing need for these agents. Additionally, advancements in surgical techniques, such as robotic-assisted surgeries, will likely drive further market demand. However, challenges such as high surgical costs, unfavorable reimbursement policies, and a lack of awareness about recent technological innovations in developing regions may impede growth. Addressing these hurdles will be crucial for harnessing the market's full potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostatic Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemostatic Agents Market Segmental Analysis

Global Hemostatic Agents Market is segmented by Type, Treatment, End User and region. Based on Type, the market is segmented into Thrombin Based Hemostats, Gelatin Based Hemostats, Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats, Fibrin Sealants and Others. Based on Treatment, the market is segmented into Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery and Others. Based on End User, the market is segmented into Hospitals, Surgery Centers, Nursing Homes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemostatic Agents Market

The global hemostatic agents market is primarily driven by the increasing frequency of surgical procedures worldwide, which has heightened the need for effective bleeding management during operations. As the number of surgeries rises, so does the incidence of bleeding complications, underscoring the importance of hemostatic products in clinical practice. Significant advancements in medical devices have enhanced the ability to achieve hemostasis, further propelling market growth. Recent data from the National Center for Biotechnology Information (NCBI) indicates that approximately 60-70% of transfused red blood cells are utilized in surgical settings, emphasizing the critical role these agents play in minimizing surgical risks and optimizing patient outcomes.

Restraints in the Global Hemostatic Agents Market

The Global Hemostatic Agents market faces several constraints that hinder its growth. One significant issue is the occurrence of uncontrolled bleeding, which poses a challenge in the widespread adoption of these agents. Although advancements have led to improved management of bleeding during surgeries and reduced infection risks, the high cost of these products remains a barrier to their utilization. Furthermore, specific surgical instruments may only be compatible with certain hemostatic agents, creating additional clinical limitations. Despite technological progress, these constraints continue to restrict the effective application of hemostatic agents in various medical scenarios, hampering their market potential.

Market Trends of the Global Hemostatic Agents Market

The Global Hemostatic Agents market is witnessing a significant trend driven by the escalating need to address hemorrhage, a leading cause of mortality in both military and civilian populations. With over 30% of traumatic deaths resulting from uncontrolled bleeding, the demand for effective hemostatic agents is surging, particularly in emergency and high-stress medical environments. These agents not only stabilize patients by mitigating risks associated with hypothermia, infections, and organ failure but also play a crucial role in trauma care. As awareness of their life-saving potential grows, investment in research and development is likely to further propel market expansion and innovation in hemostatic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostatic Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Thrombin Based Hemostats
• Gelatin Based Hemostats
• Collagen Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Global Hemostatic Agents Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Cardiovascular
• General Surgery
• Digestive Surgery
• Neurosurgery
• Others

Global Hemostatic Agents Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Global Hemostatic Agents Market Size & CAGR (2025-2032)

• North America (Type, Treatment, End User)
  • US
  • Canada
• Europe (Type, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences Holdings Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Medicines Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations